Skip to main content
ZIM Laboratories Limited logo

ZIM Laboratories Limited — Investor Relations & Filings

Ticker · ZIMLAB ISIN · INE518E01015 LEI · 335800YPYG1O3ML66R52 BSE.NS Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2024-07-27 Regulatory Filings
Country IN India
Listing BSE.NS ZIMLAB

About ZIM Laboratories Limited

https://www.zimlab.in/

ZIM Laboratories Limited is a research-driven organization specializing in the development and manufacturing of innovative drug delivery solutions. The company focuses on enhancing the efficacy and patient compliance of generic medicines through advanced formulation technologies. Its core product portfolio includes Oral Disintegrating Films (ODF), Oral Disintegrating Tablets (ODT), pellets, and taste-masked granules. Utilizing proprietary technology platforms like Thinoral, the company provides differentiated products across various therapeutic segments, including central nervous system, cardiovascular, and gastrointestinal health. ZIM Laboratories offers end-to-end services from product development and clinical trials to commercial manufacturing. The organization serves a global clientele, providing value-added generic formulations that address specific patient needs such as ease of administration and rapid onset of action.

Recent filings

Filing Released Lang Actions
Board Meeting — ZIM LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 03-Aug-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for…
Regulatory Filings
2024-07-27 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges and compliance departments informing about a scheduled Board of Directors meeting to consider and approve the unaudited financial results for the quarter ended June 30, 2024. It also mentions the closure of the trading window as per insider trading regulations. The document does not contain any financial data or detailed results but is an announcement of an upcoming event related to financial reporting. The length is only 2210 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about a board meeting and financial results approval, not the financial results report itself.
2024-07-27 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the grant of Marketing Authorization for a pharmaceutical product in Portugal by a regulatory authority. It is addressed to stock exchanges and signed by the company secretary. The content focuses on a marketing authorization event rather than financial results, management changes, or regulatory filings. The document length is short (3601 characters) and it is clearly a press release about a marketing authorization, which fits best under Capital/Financing Update (CAP) as it relates to a significant business development impacting the company's product portfolio and market presence. It is not an annual report, earnings release, or regulatory filing. Therefore, the most appropriate classification is CAP.
2024-07-22 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a formal letter from ZIM Laboratories Limited addressed to stock exchanges and shareholders regarding the transfer of unclaimed equity shares to the Investor Education and Protection Fund (IEPF) as per Indian regulatory requirements. It references specific regulations under the Companies Act, 2013 and SEBI Listing Obligations, and details the process for shareholders to claim unpaid dividends before shares are transferred to the IEPF. The content is an official announcement about a corporate action related to unclaimed dividends and share transfers, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document is a regulatory compliance announcement informing shareholders and stock exchanges about the transfer of shares to the IEPF and the related notice publication. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-07-20 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the loss of a share certificate and the consequent stop transfer of shares until a duplicate certificate is issued. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 39(3), which pertains to share certificate loss and transfer restrictions. The content is an announcement of a specific event related to share certificates and does not contain financial data, management discussion, or report publication. It is not a report or financial statement but a regulatory compliance notification about share certificate status. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-07-18 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the loss of share certificates and the consequent stop transfer of those shares until duplicate certificates are issued. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 39(3), which pertains to share certificate loss and stop transfer procedures. The content is an intimation or notification about a corporate action related to share certificates, not a financial report, audit, earnings release, or management discussion. The document length is short (2359 characters) and it serves as an official announcement to the exchanges rather than a detailed report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-12 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.